Perioperative Chemo With FLOT Ups Survival in Resectable Esophageal Cancer

Follow Drugslib on

Medically reviewed by Drugs.com.

By Elana Gotkine HealthDay Reporter

THURSDAY, Jan. 23, 2025 -- For patients with resectable esophageal adenocarcinoma, perioperative chemotherapy with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) leads to improved survival compared with preoperative chemoradiotherapy, according to a study published in the Jan. 23 issue of the New England Journal of Medicine.

Jens Hoeppner, M.D., from Bielefeld University in Detmold, Germany, and colleagues conducted a phase 3 multicenter trial involving patients with resectable esophageal adenocarcinoma who were randomly assigned to receive perioperative chemotherapy with FLOT plus surgery or preoperative chemoradiotherapy (radiotherapy at a dose of 41.4 Gy and carboplatin and paclitaxel) plus surgery (221 and 217 patients, respectively). Eligibility criteria included a primary tumor with clinical stage cT1 cN+, cT2-4a cN+, or cT2-4a cN0 disease. The primary end point was overall survival.

The researchers found that overall survival at three years was 57.4 and 50.7 percent in the FLOT and preoperative-chemoradiotherapy groups, respectively, with a median follow-up of 55 months (hazard ratio for death, 0.70). At three years, progression-free survival was 51.6 and 35.0 percent in the FLOT and preoperative-chemoradiotherapy groups, respectively (hazard ratio for disease progression or death, 0.66). Among the patients who started the assigned treatment, grade 3 or higher adverse events occurred in 58.0 and 50.0 percent of those in the FLOT and preoperative-chemoradiotherapy groups, respectively.

"The current trial showed superior overall survival with FLOT as compared with preoperative chemoradiotherapy, with a median overall survival of 66 and 37 months, respectively," the authors write.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-01-24 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords